FDA concurrence supports US launch of a 2:1 randomized ~490-patient phase 3 comparing TLX591-Tx plus SOC versus SOC in ...

The Journal of Targeted Therapies in Cancer | Targeted Publications | Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Genomic stratification (OPTIMA/Prosigna PAM50) supported endocrine-alone management for ER+/HER2– patients with low recurrence-risk scores, reframing chemotherapy benefit as largely ...

Durable ZUMA-2 follow-up converted brexu-cel to traditional approval in r/r MCL, while sonrotoclax gained accelerated approval post-BTK inhibitor based on 52% ORR. Breast-cancer decisions expanded ...

She specifically discusses the available treatment options in frontline EGFR mutation–positive advanced non–small cell lung cancer and what particular clinical and lifestyle benefits are provided by ...

Misako Nagasaka, MD, PhD, discusses practical considerations for oncologists implementing subcutaneous (SC) vs intravenous (IV) amivantamab plus lazertinib in the frontline setting for patients with ...

Misako Nagasaka, MD, PhD, discusses the overall response rate and duration of response with subcutaneous (SC) amivantamab plus lazertinib in patients with treatment-naïve, EGFR-mutated advanced ...

Misako Nagasaka, MD, PhD, explains the use of prophylactic anticoagulation for preventing venous thromboembolism (VTE) when administering amivantamab plus lazertinib in patients with EGFR-mutated ...

Misako Nagasaka, MD, PhD, discusses optimizing patient management when administering frontline SC amivantamab plus lazertinib in patients with EGFR-mutated advanced non–small cell lung cancer. She ...

Independent review–assessed PFS met the primary endpoint with zanubrutinib-rituximab versus bendamustine-rituximab (HR, 0.57; P<.0001), supporting a chemotherapy-free frontline strategy in MCL.

Explore how oncologists battle information overload, navigate conflicting trial data, and weigh AI tools while keeping ...

Targeted Oncology™ is a leading omnichannel resource for community oncologists, offering innovative learning and peer interaction through print and digital platforms. Our custom programs meet your ...